News

These data from ATS 2025 point to climate change as a potential influence on the burden associated with obstructive sleep apnea (OSA).

Pande explains findings from his research on immunosuppression in interstitial lung disease suggesting this treatment does not affect fibrosis progression.

Over 60% of patients admitted to the ICU with ARF experienced some degree of sleep disturbance after admission.

In this interview at ATS 2025, Reingold highlighted his presentation on the global immunization divide and overcoming barriers to universal vaccine coverage.

These data, presented at ATS 2025, highlight the efficacy results of methotrexate when compared to prednisone for pulmonary sarcoidosis.

New research sheds light on improved waitlist outcomes after new allocation guidelines for lung transplants prioritizing medical urgency were implemented.

At 2025 New Wave Dermatology, Zirwas highlights the most useful dermatology studies from the past 2 years, covering AD misdiagnosis, alopecia, contact dermatitis, and more.

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Discover expert insights and practical guidance in psychiatry with The Gus Alva Perspective, our latest expert-led multimedia offering.

Associations were particularly strong for people with severe COPD.

Zirwas outlines a 4-visit approach to diagnosing spongiotic dermatitis, helping dermatologists manage uncertain rashes more effectively.

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

At New Wave Derm 2025, Kalil shared expert tips on evaluating and diagnosing scarring vs non-scarring hair loss using clinical tools.

Vapendavir shows promise in reducing respiratory symptoms and illness duration in COPD patients infected with rhinovirus.

Children with KCN have greater risk of progression than adults; study findings suggest CXL may slow that progression or prevent it altogether.

Hosts explore the latest advancements in amyloidosis treatment, with expert insights on emerging therapies and patient care strategies.

Kalil discusses the latest advancements in hair loss treatments, including innovative therapies and ongoing research in dermatology for effective solutions.

Guan describes the potential value of using wearable devices to enhance IBS management by tracking sleep and exercise.

This interview with Jennifer Soung, MD, highlights the implications of recent phase 3 findings on roflumilast foam 0.3% (Zoryve) for psoriasis of the scalp and body.

Findings suggest a connection between RVO history and cystoid macular edema with the risk of developing postoperative macular edema after uneventful cataract surgery.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

Kendall E. Donaldson, MD, discusses the significant impact of lotilaner ophthalmic solution on symptoms in patients with Demodex blepharitis in the Orion registry.

With the sNDA acceptance, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.

In this retrospective study, investigators highlight the effectiveness and safety of baricitinib and systemic corticosteroid addition for alopecia areata.

Banerjee describes the value of multiorgan MRI for predicting cardiac and liver outcomes and cT1’s prognostic utility in liver disease.

The recent analysis has indicated the implant’s relative success in maintaining treatment for NIU without need for supplementary treatments.